

# WELLFULLY

**COMPANY PRESENTATION** 

OCTOBER 2022

## DISCLAIMER



This presentation contains certain "forward-looking statements" concerning Wellfully. Where Wellfully expresses or implies an expectation or belief as to future events or results, such expectation or belief is expressed in good faith and believed to have a reasonable basis.

Forward-looking statements provided in this announcement are based on assumptions and contingencies which are subject to change without notice. Such forward-looking statements including statements regarding intentions, planned events and potential results are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance.

There can be no assurance that actual outcomes will not differ materially from these forward-looking statements, and there are risks associated with Wellfully and the industry which may affect the accuracy of the forward-looking statements. Wellfully does not undertake any obligation to release publicly any revisions to any forward-looking statements to reflect events or circumstances after the date of this announcement or to reflect the occurrence of unanticipated events, except as may be required under applicable securities laws.

## WELLFULLY INVESTMENT HIGHLIGHTS



#### A HIGHLY INNOVATIVE WELLNESS COMPANY WITH GLOBALLY DISRUPTIVE PRODUCTS

#### About Wellfully Limited (ASX:WFL)

Wellfully Limited ('Wellfully' or 'the Company') is the world's first fully-integrated, science-based wellness company. Over the past two years, the Company has leveraged its vast enhanced drug deliveries technology inventory and developed industrial infrastructure and its own product portfolio.


Wellfully is active in the highly attractive beauty and personal care, beauty device, as well as the health and pain relief markets delivering innovative products through collaborations with industry majors spanning licensing, joint development and OEM, as well as with its own global cosmetic and healthcare brands, RÉDUIT and SWISSWELL, positioned to disrupt these global blockbuster markets.

Supported by a highly experienced Board and Management, Wellfully is poised to deliver notable and sustainable results.

#### Corporate Snapshot\*

Share Price	\$0.027
Shares on Issue	~278.7m
Options on Issue (\$0.15 exercise)	~200.9m
Market Capitalisation	~\$7.5m
Cash (30 June 2022)	~\$318k
Top 20	40.7%
Board & Management	7.0%

#### Share Price Performance



<sup>\*</sup>Share price, market capitalisation, share holdings as at 4 October 2022

## A FULLY-INTEGRATED SCIENCE-BASED WELLNESS COMPANY




WITH FY2022 WELLFULLY HAS COMPLETED ITS TRANSFORMATION FROM AN R&D LICENSING BUSINESS

### PROPRIETARY TECHNOLOGIES

+25 years of research with global majors

+17 patents covering key company technologies

Beauty & Pharma clinical-study supported



ENHANCED DRUG
DELIVERY, the proven ability
to move active ingredients
from formulations to where
they are needed, in a
controlled way – and the
know-how to turn these
technologies into products!

#### BEST-IN-CLASS TRACK RECORD









# INTEGRATED OPERATIONS

GMP Certified formulations plant

SWISS Made topical production

Medical Class 1
Device product registrations



# VERTICALLY INTEGRATED OPERATION:

- Product & process R&D
- Industrialisation
- Formulation creation
- Device manufacturing
- Distribution & MKTG
- In-house brands

IN-HOUSE CONSUMER BRANDS

#### **SWISSWELL**

RÉDUIT

# DIGITAL PLATFORM

+1.5 million 3rd party product formulations

+23.000 parameters for different users

+33 active ingredients enhanced with waveforms



THE ONLY UNIVERSAL POINT-OF-USE APP across health and beauty applications for 3<sup>rd</sup> party topical products available today, active for over 1.5 million formulations – still growing its perimeter.

#### SKINCARE USE DATA



# OWN PRODUCTS AND BRANDS HAVE BECOME CORE



WITH FY2022 THE NEW MODEL HAS BECOME DOMINANT

#### REDUCING EXPOSURE & CAPTURING MORE VALUE

Own products and brands have become central

#### THE REVENUES ARE EVOLVING IN LINE WITH STRATEGY


Revenue evolution by business FY2020-2022, in 000 A\$

#### The 2018 development plan:

- Reduce reliance on few large partners and government subsidies
- Develop Infrastructure designed to capture more value with own products and brands

#### The FY2022 revenue evolution:

- + 2x overall vs FY 2021
- + 5x own products & brands vs FY 2021



In hindsight, the 2019 plan worked even better than anticipated with own product and brand revenues also compensating the COVID-19-driven decline in traditional technology licensing business

# FY2022 SAW REVENUE GROWTH FROM RÉDUIT & OWN PRODUCTS WELLFULLY

ACTIVITIES AROUND OWN PRODUCTS AND BRANDS INCREASING


#### **RÉDUIT DEVELOPMENTS**

Key milestones achieved in FY2022

REDUIT APARes	Sep-21	RÉDUIT haircare for Victoria Beckham at London Fashion Week
Harrods	Mar-22	RÉDUIT launches in Harrods London with a dedicated event
	Mar-22	RÉDUIT BOOST is launched at the WOW Madrid store opening
	Mar-22	RÉDUIT BOOST receives best product award at Cosmoprof
SEPHORA	Apr-22	RÉDUIT launches across Sephora Brazil stores with full range
SWISS M A D E	Apr-22	Approval for the use of the SWISS MADE label received

#### **REVENUE EVOLUTION**

RÉDUIT brand and product revenues., FY2020-2022, in 000 A\$



With sales more than doubling y-o-y, RÉDUIT is in line with its development targets. In FY2022, the focus remains on commercial scaling and the development of new retail partners across key markets.

## IMPORTANT MILESTONES ACHIEVED BY SWISSWELL



THE SWISSWELL LUBRICEN KNEE PATCH IN FY2022

**GO-LIVE** 





Aug-21

Following 5 years of development, the SWISSWELL Lubricen Knee Patch was launched DTC-only.

REGULATORY APPROVALS





Apr-22

Market approval as a Class 1 Medical Device and pain relief claims in the US and the EU

GMPc & SWISS MADE





Apr-Jul-22

Wellfully's Lugano operation receives Swiss Made label, as well as GMPc certification (ISO 22716).

In FY2022, Wellfully secured important advancements and regulatory product qualifications for its most innovative and differentiated product, the SWISSWELL Lubricen Knee Patch

# SWISSWELL LUBRICEN KNEE PATCH

A CLINICALLY PROVEN REVOLUTION IN PAIN MANAGEMENT




#### DRUG-FREE TOPICAL RELIEF

A synthetic blend of key ingredients known to support the lubrication of the knee. Safe for regular and ongoing use.



Highly effective delivery of SWISSWELL's drug free actives, provides immediate results.

# GLUCOSAMINE PENETRATION OVER TIME



#### A SAFE ONGOING JOINT MAINTENANCE REMEDY

Drug-free topical patch which supports joint function and the lubrication of the knee, mobility and flexibility with the diamagnetic micro-array technology outperforming NSAIDs.



# THE PRODUCT SPEAKS FOR ITSELF

# WELLFULLY


EXTRAORDINARY FEEDBACK FROM INITIAL SALES





#### Based on 64 Reviews





92% reviewers would recommend this product











#### 1st EXPERIENCES

#### **IT WORKS**

In a world full of overpromise and underdelivery, consumers are delighted by the effectiveness of the SWISSWELL product

# Less pain, more performance

Contrary to most painrelief-only, many consumers focused their feedback on the added performance

#### Drug free!

An effective, drug-free alternative to NSAIDs provides for a unique continuous use solution

#### Deliveries?


Product availability with existing suppliers is an issue - see the **patch** insourcing section.

Note: the 4.7 rating is product evaluations w/o 8 1\* reviews removed as related to deliveries for a gross rating of 4.3\*

# **ACCELERATING WORD-OF-MOUTH**

# WELLFULLY

#### GROWING AWARENESS WITH PRODUCT MARKETING CAMPAIGNS


















#### PRODUCT-IN-HAND

#### Efficient sampling

100s of products being distributed with the new samples pack in the UK and the US

#### KOLs and

Influencers growing the earned perimeter, targeting sports health and physio specialists in key markets

#### **B2B Sampling**

contracting sampling with distribution activities within the new pharma channels

#### **Product reviews**

sampling also part of PR activities with structured product evaluation partners

## CRITICAL SOURCING BOTTLENECKS



CONSTRAINTS IN SCALING SWISSWELL

#### AVAILABILITY

- Long supply-chain: transformers and ingredient/component suppliers.
- +6 months lead-times (up to 10 total)
- Little control to accelerate, seek alternatives

#### **SWISSWELL LUBRICEN**

Supply-chain map

#### COSTS

- High structural costs (eg hydrogel at US\$ +0.50/unit)
- Exposure to price increases (passed on)
- Little control in optimisation, alternatives to reduce costs (transformers' supply-chains, technology)

# Magnetic Micro-arrays Foils & Liners PARAFIX Engineered Adhesive Solutions

#### **RANGE**

- Long and rigid chain (locked in current tech)
- Opportunity to extend to other joints with Lubricen
- Opportunities in developing other formulations and enhancing other active ingredients.

Current patch sourcing strategy sets limitations on market access: costs and competitiveness, as well as service levels - the ability to be flexible in supply, and possible range extensions.

# **INSPECTING ALTERNATIVES FEB-AUG 2022**



SYSTEMATIC EVALUATIONS ACROSS PRODUCT AND PROCESS

EXISTING HYDROGEL

- Stable and performing (permeability touch-feel)
- Asset intensive (high costs, long lead-times)
- · Slow to optimise existing and develop new formulations




GELATINE MATRIX

- Flexible for different formulations (gel)
- Product stability (matrix)
- Process feasibility and quality (non-continuous)



OFFSET GEL PRINT

- Flexible for different formulations (gel)
- Continuous process
- Process stability and quality (gel vs inert component)



MICRO-ARRAY LAMINATE

- Flexible for different formulations (gel)
- Process stability and quality
- Continuous process constraints (thermal processing)



Over the past 6 months, multiple options for changing the structure and insourcing have been evaluated by the product, R&D and industrialization teams.


# BREAKTHROUGH INSOURCING SOLUTION AT -67% COST



PRODUCT AND PROCESS PLAN FOR THE NON-WOVEN-TEXTILE PATCH

#### PRODUCT STRUCTURE

- Active formulation applied to a nonwoven material substrate
- Micro-array, kinesiology tape as is




67% COSTS REDUCTION

Lubricen unit costs. US\$

#### PRODUCT PERFORMANCE

- Good formulation release
- Good product stability
- OK for multiple formulations








#### PROCESS PERFORMANCE

- Continuous, flexible process
- Stable good quality performance expected





# FACILITY INTEGRATION

- Co-location at existing Lugano facility
- Regulatory adjustment: GMPc -> GMPp qualification







Note: \*the US\$ 3.8 average sales price (ASP) is based on a 50-50% distribution between B2C (US\$ 4.5 ASP(), and B2B (US\$ 2.0 ASP).

The gel-in-non-woven-textile solution has been selected for industrialization as the superior product and process structure in terms of performance, cost and feasibility.

## **GETTING TO MAINSTREAM ECONOMICS IN FY2023**



BUSINESS IMPLICATIONS OF THE NEW PATCH STRUCTURE


#### INCREASING ACCESS TO MARKETS ...

Cost structure is limiting access to market and channels

#### **Currently Accessible** With US\$ 1.50 cost per patch 50% B2B and 50% B2C for a B<sub>2</sub>C total of 0.5 M units Selective\ **Additional Access Lloyds**Pharma With US\$ 0.50 cost per patch 87.5% B2B and 12.5% B2C for Long-chain a total of 2.0 M units Alliance Healthcare **New Products\*** Modern Other Lubricen distribution joint patches and new formulations Walgreens are not included!

#### ... SIGNIFICANTLY IMPACTING FINANCIALS

Scenario gross margin contribution changes, in 000 USD\$



Insourcing the patches allows for competitiveness and service/availability needed to serve the mainstream markets resulting in an important positive impact on the overall business.

# **KEY ASSETS AND FOCUS AREAS IN FY2023**



CONTINUATION OF DEVELOPMENT ACTIVITIES

# COMMERCIAL DEVELOPMENT

- Continue development of the RÉDUIT portfolio
- Build presence of SWISSWELL existing product (certifications)

# IN-HOUSE PATCH PRODUCTION

- Ensure SWISWELL competitiveness and availability
- Leverage existing Lugano operation and regulatory approvals

# SCALING EXISTING INFRASTRUCTURE

- Continue development of collaborations
- Seek cost efficiencies in existing perimeter

